What's Next for Endava plc Shareholders After 24.37% Stock Drop? Glancy Prongay Wolke & Rotter LLP Explains Securities Fraud Class Action Lead Plaintiff Deadline

Endava ADS fell $0.68, or 24.37%, to $2.11 on September 22, 2026, after the company announced its CFO had been placed on administrative leave pending an independent investigation into accounting treatment of certain customer and supplier agreements. A securities class action alleges investors were misled about the accounting review, a delay to fourth-quarter and full-year 2026 results, and the effectiveness of internal controls; these are allegations, and no class has been certified. Investors seeking lead plaintiff status must file by November 30, 2026.

Analysis

The securities suit is not the key incremental risk; the auditor-raised accounting questions, CFO leave, and delayed results create a credibility and information-risk discount. Until Endava quantifies any accounting adjustments and establishes reporting reliability, investors cannot confidently underwrite earnings or cash conversion. If customer or supplier arrangements were recorded in ways that overstated revenue or understated costs, the impact could extend beyond a one-period restatement to renewed diligence by clients and longer sales cycles. That is a conditional risk, not an established finding.

Over the next 1–3 months, the fundamental catalysts are the investigation’s conclusions, audited results, and any control-deficiency or guidance disclosures. The November 30 lead-plaintiff deadline is procedural and should not, by itself, drive valuation. Over 6–18 months, confirmed control weaknesses could increase compliance costs and impede client wins; competitors such as EPAM Systems (EPAM), Globant (GLOB), and Accenture (ACN) could be considered by customers, though no displacement is established. The contrarian point: the initial repricing may already reflect substantial uncertainty, while the downside remains unusually hard to bound without the missing financial detail. Treat the complaint’s claims as allegations, not proof.

Key Decisions for Investors

• Keep DAVA underweight and avoid averaging down before the company publishes the investigation findings and delayed financials. Reassess when revenue recognition, cash-flow effects, and control conclusions are quantified.
• For existing exposure, consider a defined-risk DAVA put spread rather than an outright short, but only after checking current option liquidity, implied volatility, and borrow/price conditions; the large gap makes unhedged downside trades vulnerable to sharp reversals.
• Do not initiate a long EPAM/GLOB/ACN pair solely on presumed share gains. Put these names on a relative-performance watchlist and seek evidence of customer wins or pipeline changes before expressing a competitor-benefit thesis.
• Falsifiers: a timely, independently supported resolution with no material adjustment and effective controls would weaken the underweight thesis. Material restatement, auditor qualification or resignation, further reporting delays, or deteriorating guidance would strengthen it.